Goldman Sachs says it continues to prefer Syngene and Neuland over Divi’s, on which it has a neutral call, and Gland Pharma and Laurus Labs, which it recommends selling.
Goldman Sachs says it continues to prefer Syngene and Neuland over Divi’s, on which it has a neutral call, and Gland Pharma and Laurus Labs, which it recommends selling.